Clinical Epidemiology & Biostatistics


Shamir Mehta

BSc (Toronto), MD (Toronto), MSc (McMaster), FRCPC


Professor, Department of Medicine (Cardiology)

Associate Member, Dept of Clinical Epidemiology & Biostatistics

Director, Interventional Cardiology, Hamilton Health Sciences

Director, Interventional Cardiology and Acute Coronary Syndrome Research Program, Population Health Research Institute.

Staff Cardiologist, Hamilton Health Sciences

CIHR New Investigator Award 2003-2008

905.521.2631
905.296.0086
smehta@mcmaster.ca

Hamilton Health Sciences
General Division
David Braley CVSRI Building
C3-11A
237 Barton Street East
Hamilton, Ontario, Canada
L8L 2X2

Administrative Assistant: Nina Ormerod
ormerodj@HHSC.ca

 

Selected Publications

  1. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht J-J, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S; TIMACS Investigators. Early versus Delayed Invasive Management of Acute Coronary Syndromes. N Engl J Med 2009;260:2165-75
  2. Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine versus selective invasive strategies in patients with acute coronary syndromes: A collaborative meta-analysis of the randomized trials. JAMA 2005; 293(23): 2908-2917
  3. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H-J, Zhao F, Chrolavicius S, Copland I and Fox KAA for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
  4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KAA for the CURE Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events Trial (CURE) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
  5. Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003; 41: 78S-87S
  6. Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jollly S, Granger CB, Fox KA, Bassand JP, Yusuf S; OASIS 5 and 6 Investigators. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST-and non-ST-segment elevation acute coronary syndromes; an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008;118(20):2038-46
  7. Mehta SR, Granger CB, Eikelboom JW, Bassand J-P, Wallentin L, Faxon DP, Peters RJG, Budaj A, Afzal R, Chrolavicius S, Fox KAA, Yusuf S. Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial. J Am Coll Cardiol 2007; 50(18): 1742-1751
  8. Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJG, Bassand J-P, Budaj A, Joyner C, Chrolavicius S, Fox KAA for the OASIS 5 Steering Committee. Design and Rationale of the MICHELANGELO OASIS-5 Trial Program Evaluating Fondaparinux, a Synthetic Factor Xa Inhibitor, in patients with non-ST segment Elevation Acute Coronary Syndromes. Am Heart J 2005; 150: 1107 e1-e10.
  9. Mehta SR, Steg G, Granger CB, Bassand J-P, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJG, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay J-F, Fox KAA, Yusuf S. for the ASPIRE Pilot Investigators. A randomized blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention. The Arixtra Study in Percutaneous Coronary Intervention: A randomized evaluation (ASPIRE) Pilot Trial. Circulation 2005; 111: 1390-1397
  10. Yusuf S, Mehta SR for the CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293(4): 427-436

Search for citations for Dr. Mehta on PubMed